On Mar. 10, 2021, Thermo Fisher Scientific announced more than $600 million in capital investments to expand its bioprocessing production capabilities through 2022.

These investments were expected to more than double the company’s manufacturing capacity and support customers ramp up to meet both the short-term demands related to COVID-19 as well as long-term efforts to develop new vaccines and biologics for other conditions.